BioStock: Arcede Pharma share under pressure despite development progress

Lund-based Arcede Pharma has had a tough start to its journey as a listed company after the spin-off from Respiratorius this summer. The ice cold stock market environment has weighed on the company’s shares. At the time of writing, the share is trading at well below Arcede Pharma’s cash position, despite the fact that the development is going according to plan. Here, BioStock looks closer at how the market values the potential that the company believes is present in the research.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/arcede-pharma-share-under-pressure-despite-development-progress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se